Literature DB >> 7694896

Lipoylated and unlipoylated domains of human PDC-E2 as autoantigens in primary biliary cirrhosis: significance of lipoate attachment.

J Quinn1, A G Diamond, J M Palmer, M F Bassendine, O F James, S J Yeaman.   

Abstract

Approximately 95% of patients with primary biliary cirrhosis have antimitochondrial antibodies against the E2 component of the pyruvate dehydrogenase complex (E2p). Immunodominant sites on E2p have been localized to the inner lipoyl domain, which serves as a covalent attachment site for the essential cofactor, lipoic acid. However, it is not clear whether the presence of lipoic acid is necessary for autoimmune recognition of human E2p. To facilitate further studies on the inner lipoyl domain and to assess the importance of lipoic acid in antibody binding, we used the previously cloned human E2p cDNA in the construction and high-level expression in Escherichia coli of a subgene encoding the domain. Purification and analysis of the gene product revealed that both lipoylated and unlipoylated forms of the intact domain are generated. Immunoblotting, enzyme-linked immunosorbent assay inhibition experiments and antibody affinity measurements using isolated lipoylated and unlipoylated domains demonstrated that the presence of the lipoyl residue is crucial for effective recognition by primary biliary cirrhosis patients' autoantibodies, which have a higher relative affinity for the lipoylated form. Contrary to some previous suggestions, these results indicate that antibodies in primary biliary cirrhosis patients' sera bind most effectively to a unique peptide-cofactor conformation in the lipoyl domain of the human E2p polypeptide. Moreover, the availability of large amounts of human lipoyl domain will permit further studies into the role of the antigen (if any) in disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694896

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

Review 1.  Sidechain biology and the immunogenicity of PDC-E2, the major autoantigen of primary biliary cirrhosis.

Authors:  Tin K Mao; Paul A Davis; Joseph A Odin; Ross L Coppel; M Eric Gershwin
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

Review 2.  Pathogenesis of primary biliary cirrhosis.

Authors:  David E J Jones
Journal:  Gut       Date:  2007-07-19       Impact factor: 23.059

3.  T cell responses to the putative dominant autoepitope in primary biliary cirrhosis (PBC).

Authors:  J M Palmer; A G Diamond; S J Yeaman; M F Bassendine; D E Jones
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

4.  Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis.

Authors:  J A Odin; R C Huebert; L Casciola-Rosen; N F LaRusso; A Rosen
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 5.  Autoantigens in primary biliary cirrhosis.

Authors:  D E Jones
Journal:  J Clin Pathol       Date:  2000-11       Impact factor: 3.411

6.  Secretory autoantibodies in primary biliary cirrhosis (PBC).

Authors:  J M Palmer; M Doshi; J A Kirby; S J Yeaman; M F Bassendine; D E Jones
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

Review 7.  The enigma of primary biliary cirrhosis.

Authors:  Carlo Selmi; Yasunori Ichiki; Pietro Invernizzi; Mauro Podda; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 8.  Bacteria and primary biliary cirrhosis.

Authors:  Dimitrios P Bogdanos; Diego Vergani
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

Review 9.  The autoimmunity of primary biliary cirrhosis and the clonal selection theory.

Authors:  Carlo Selmi; Ian R Mackay; M Eric Gershwin
Journal:  Immunol Cell Biol       Date:  2010-10-26       Impact factor: 5.126

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.